Bridging basic science and applied diagnostics: Comprehensive viral diagnostics enabled by graphene-based electronic biosensor technology advancements.

COVID-19 Diagnostics Graphene field-effect transistor Infectivity Nucleocapsid protein SARS-CoV-2

Journal

Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289

Informations de publication

Date de publication:
21 Sep 2024
Historique:
received: 09 07 2024
revised: 02 09 2024
accepted: 19 09 2024
medline: 29 9 2024
pubmed: 29 9 2024
entrez: 28 9 2024
Statut: aheadofprint

Résumé

This study presents a graphene field-effect transistor (gFET) biosensor with dual detection capabilities for SARS-CoV-2: one RNA detection assay to confirm viral positivity and the other for nucleocapsid (N-)protein detection as a proxy for infectiousness of the patient. This technology can be rapidly adapted to emerging infectious diseases, making an essential tool to contain future pandemics. To detect viral RNA, the highly conserved E-gene of the virus was targeted, allowing for the determination of SARS-CoV-2 presence or absence using nasopharyngeal swab samples. For N-protein detection, specific antibodies were used. Tested on 213 clinical nasopharyngeal samples, the gFET biosensor showed good correlation with RT-PCR cycle threshold values, proving its high sensitivity in detecting SARS-CoV-2 RNA. Specificity was confirmed using 21 pre-pandemic samples positive for other respiratory viruses. The gFET biosensor had a limit of detection (LOD) for N-protein of 0.9 pM, establishing a foundation for the development of a sensitive tool for monitoring active viral infection. Results of gFET based N-protein detection corresponded to the results of virus culture in all 16 available clinical samples and thus it also proved its capability to serve as a proxy for infectivity. Overall, these findings support the potential of the gFET biosensor as a point-of-care device for rapid diagnosis of SARS-CoV-2 infection and indirect assessment of infectiousness in patients, providing additional information for clinical and public health decision-making.

Identifiants

pubmed: 39341071
pii: S0956-5663(24)00813-3
doi: 10.1016/j.bios.2024.116807
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116807

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Robert Strassl reports financial support was provided by Austrian Science Fund. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anna Nele Herdina (AN)

Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria.

Anil Bozdogan (A)

Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria; BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria.

Patrik Aspermair (P)

BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria; Life Sciences Technology, Danube Privat University, Wiener Neustadt, Austria.

Jakub Dostalek (J)

Life Sciences Technology, Danube Privat University, Wiener Neustadt, Austria; Institute of Physics, Czech Academy of Sciences, Prague, Czech Republic.

Miriam Klausberger (M)

Department of Biotechnology, BOKU University, Vienna, Austria.

Nico Lingg (N)

ACIB - Austrian Centre of Industrial Biotechnology, Vienna, Austria; Department of Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria.

Monika Cserjan-Puschmann (M)

ACIB - Austrian Centre of Industrial Biotechnology, Vienna, Austria; Department of Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria.

Patricia Pereira Aguilar (PP)

ACIB - Austrian Centre of Industrial Biotechnology, Vienna, Austria; Department of Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University, Vienna, Austria.

Simone Auer (S)

BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria.

Halil Demirtas (H)

BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria.

Jakob Andersson (J)

BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria; Institute of Science and Technology Austria, Klosterneuburg, Austria.

Felix Lötsch (F)

Division of Clinical Microbiology, Medical University of Vienna, Vienna, Austria; Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.

Barbara Holzer (B)

Institute Krems Bioanalytics, IMC Krems University of Applied Sciences, Krems, Austria.

Adi Steinrigl (A)

Austrian Agency for Health and Food Safety (AGES), Institute for Veterinary Disease Control Mödling, Mödling, Austria.

Florian Thalhammer (F)

Department of Urology, Medical University of Vienna, Vienna, Austria.

Julia Schellnegger (J)

Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria.

Monika Breuer (M)

Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria.

Wolfgang Knoll (W)

BioSensor Technologies, Austrian Institute of Technology, Vienna, Austria; Life Sciences Technology, Danube Privat University, Wiener Neustadt, Austria.

Robert Strassl (R)

Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Vienna, Austria. Electronic address: Robert.strassl@meduniwien.ac.at.

Classifications MeSH